Skip to main content
PepStack
Hormone · Profile

Testosterone

Testosterone Enanthate · Testosterone Cypionate · Testosterone Propionate · Testosterone Undecanoate

Sex Hormones & TRTApproved
MW
288.4g/mol
Formula
C19H28O2

Testosterone is a steroid hormone classified as an androgen, primarily produced in the testes in males and in smaller amounts in the ovaries and adrenal glands in females. Researchers primarily study testosterone for its role in regulating various physiological processes, including muscle mass, strength, and sexual function. Key findings from studies indicate that testosterone administration is associated with dose-dependent increases in muscle mass and strength, as well as changes in fat mass and certain blood parameters. Additionally, clinical evidence indicates that testosterone deficiency can impact secondary sexual characteristics and overall health in men, leading to ongoing research into its therapeutic applications. Current investigations continue to explore the complexities of testosterone's effects and its potential clinical relevance in treating conditions related to hormonal imbalances.

Overview

Übersicht

Testosterone is a steroid hormone primarily produced in the testes in males and in smaller amounts in the ovaries in females, as well as the adrenal glands in both sexes. It belongs to the androgen class of hormones and is responsible for the development of male secondary sexual characteristics. Synthetic forms of testosterone, such as testosterone enanthate, cypionate, and propionate, are used in clinical settings for hormone replacement therapy. Researchers have extensively studied testosterone's role in various physiological processes, including its effects on muscle mass, strength, and body composition. It is also involved in regulating sexual function, mood, and cognitive abilities. Testosterone acts through androgen receptors, influencing gene expression and promoting protein synthesis, which contributes to its anabolic effects on muscle tissue. The pharmacokinetic properties of testosterone vary by its form; for instance, testosterone enanthate and cypionate are long-acting esters administered via intramuscular injection, while testosterone propionate is shorter-acting. Testosterone is metabolized in the liver and excreted in urine. Clinically, testosterone is used to treat hypogonadism and other conditions associated with testosterone deficiency. It is regulated as a controlled substance in many countries due to its potential for misuse in enhancing athletic performance.

Chemical profile

Chemische Struktur

Chemical structure of Testosterone
FormelC19H28O2
Molekulargewicht288.4g/mol
CAS-Nummer58-22-0
PubChem CID6013
Mechanism

Wirkmechanismus

Testosterone exerts its effects primarily by binding to androgen receptors, which then translocate to the cell nucleus and modulate gene expression. This interaction promotes anabolic processes such as protein synthesis, leading to increased muscle mass and strength.

Mechanism

Signalweg

Testosterone exerts its biological effects primarily through binding to androgen receptors (AR) in target tissues, initiating androgen receptor signaling pathways that regulate gene expression involved in muscle protein synthesis, muscle mass increase, and fat metabolism. This interaction activates intracellular signaling cascades, including the phosphoinositide 3-kinase (PI3K)/Akt pathway, which promotes muscle hypertrophy and inhibits protein degradation. Additionally, testosterone influences the production of insulin-like growth factor I (IGF-I), further contributing to anabolic processes, although the complete mechanism of action remains partially understood.

Half-Life & Pharmacokinetics

ENEndogenous

Circulating half-life ~70 minutes

IMIntramuscular

~8 days (enanthate ester), ~14 days (cypionate ester)

TDTransdermal

Steady-state after 24-48h

POOral

Poor bioavailability due to first-pass metabolism

Testosterone enanthate and cypionate are long-acting esters, while propionate is shorter-acting.

Storage

Temperature

Store at room temperature (15-30C)

Light

Protect from light

Form

Oil solution stable for 2+ years

Notes

Ensure vials are tightly sealed to prevent contamination.

Solubility

Löslichkeit

Testosterone is soluble in oil, which is relevant for its formulation as an injectable solution.

Legal Status

🇩🇪DE

Verschreibungspflichtig; controlled under BtMG.

🇺🇸US

FDA approved; Schedule III controlled substance; prescription required.

🇦🇺AU

Schedule 4 (S4) prescription-only medicine.

🇬🇧UK

Prescription-only medicine (POM); regulated by MHRA.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Open Questions

Offene Forschungsfragen

Current evidence is limited regarding the specific dose-response relationships of testosterone across various androgen-dependent processes, as existing studies primarily focus on muscle mass and strength without adequately addressing cognitive and sexual functions. Further research is needed through larger randomized controlled trials (RCTs) that explore the long-term effects of different testosterone doses on a broader range of physiological outcomes, particularly in diverse populations including older men and those with comorbidities. Additionally, the impact of testosterone therapy on mental health and cognitive function remains underexplored, necessitating studies that assess these effects over extended periods.

83 Research Publications

4,722

Total Citations

41

Human/RCT

4.8

Avg. Influence

2025

Latest

Sort
Filter
#01

The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.

Bhasin S, et al. · The New England journal of medicine · 1996

HumanInfluence52.0
1044
The study demonstrated that supraphysiologic doses of testosterone, particularly when combined with exercise, significantly increased fat-free mass, muscle size, and strength in normal men.

Key findings

  1. 01Testosterone increased muscle size in both arms and legs compared to placebo.
  2. 02Participants combining testosterone with exercise gained more fat-free mass and strength than those who did not exercise.
  3. 03Mood and behavior remained unchanged across all groups.
#02

Testosterone dose-response relationships in healthy young men.

Bhasin S, et al. · American journal of physiology. Endocrinology and metabolism · 2001

HumanInfluence26.0
910
Researchers observed that testosterone administration in healthy young men resulted in dose-dependent increases in fat-free mass, muscle size, strength, and power, while different androgen-dependent processes exhibited varying testosterone dose-response relationships.

Key findings

  1. 01Higher testosterone doses resulted in greater increases in fat-free mass and muscle strength.
  2. 02Changes in muscle size and strength were closely linked to testosterone levels.
  3. 03Sexual function and cognitive abilities did not significantly change with varying testosterone doses.
#03

Effect of testosterone on muscle mass and muscle protein synthesis.

Griggs R C, et al. · Journal of applied physiology (Bethesda, Md. : 1985) · 1989

HumanInfluence11.0
489
The study demonstrated that testosterone enanthate increased muscle mass by 20% and muscle protein synthesis by 27% in normal male subjects, indicating its anabolic effects.

Key findings

  1. 01Muscle mass increased by 20% on average.
  2. 02Muscle protein synthesis increased by 27%.
  3. 03Total body potassium also increased significantly.
#04

Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis.

HumanInfluence11.0
321
The study demonstrated that long-term testosterone replacement therapy in older hypogonadal males was well tolerated, with significant improvements in libido and a notable increase in hematocrit levels.
#05

Effect of testosterone cypionate on postexercise ST segment depression.

HumanInfluence7.0
156
Researchers observed that testosterone cypionate treatment significantly reduced postexercise ST segment depression in men with baseline ST segment abnormalities.
#06

Effects of testosterone replacement on sexual behavior in hypogonadal men.

HumanInfluence3.0
154
The study demonstrated that testosterone replacement improved sexual behavior in hypogonadal men, with a critical testosterone threshold identified between 2.0 and 4.5 ng/ml.
#07

Testosterone treatment comes of age: new options for hypogonadal men.

ReviewInfluence7.0
138
The study demonstrated that recent advancements in testosterone replacement therapies provide more effective and patient-friendly options for managing male hypogonadism.
#08

Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men.

HumanInfluence2.0
136
The study demonstrated that testosterone enanthate injections maintained eugonadal hormone levels in hypogonadal men for up to 11 days, supporting a dosing regimen of 200 mg every 10 to 14 days.
#09

Hormonal therapy of male hypogonadism.

ReviewInfluence5.0
114
Researchers found that androgen replacement therapy effectively induces and maintains normal secondary sexual characteristics and sexual function in males with hypogonadism.
#10

Low dose of cyproterone acetate and testosterone enanthate for contraception in men.

HumanInfluence2.0
103
Researchers observed that a low dose of cyproterone acetate combined with testosterone enanthate achieved azoospermia in a majority of men, suggesting potential for male contraception.

Clinical Trials (33)

Preclinical
Phase I
Phase II
Phase III
Approved

33

Total Trials

2,864

Total Enrolled

Effect of Testosterone Pretreatment in POR

NCT04602143COMPLETED
Sponsor

Hanoi Medical University

Enrollment

165

Started

2018

Primary outcome

Number of oocytes retrieved

Infertility

The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

NCT04134130COMPLETED
Sponsor

Lund University

Enrollment

33

Started

2019

Primary outcome

PSA-concentration

Prostate Cancer Recurrent

Perioperative Testosterone Replacement Therapy in Sarcopenic Male Colorectal Cancer Patients

Sponsor

London North West Healthcare NHS Trust

Enrollment

30

Started

2022

Primary outcome

Number of days required for a patient to be recruited on the study and how many patients are recruited

Colorectal CancerSarcopeniaHypogonadism, MalePerioperative CareTestosterone Replacement Therapy

Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients

NCT00847314COMPLETED
Sponsor

Bayer

Enrollment

30

Started

2007

Primary outcome

Waist Circumference

Hypogonadism

Androgen Effects in HIV-infected Women

NCT00095212COMPLETED
Sponsor

Massachusetts General Hospital

Enrollment

25

Started

2004

Primary outcome

Lean Body Mass

HIV Infection

Purification of Testis-Stimulating Factor in Precocious Puberty

NCT00004344COMPLETED
Sponsor

National Center for Research Resources (NCRR)

Enrollment

4

Started

1997

Precocious Puberty

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350Phase 4RECRUITING
Sponsor

Roswell Park Cancer Institute

Enrollment

600

Started

2025

Primary outcome

Gleason grade progression

Localized Prostate CarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8

Testosterone Replacement in Men With Diabetes and Obesity

NCT01127659Phase 4COMPLETED
Sponsor

University at Buffalo

Enrollment

137

Started

2010

Primary outcome

Insulin Sensitivity

Hypogonadism

Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT01403116Phase 3COMPLETED
Sponsor

Clarus Therapeutics, Inc.

Enrollment

325

Started

2011

Primary outcome

Percentage of Treated Patients With Average Serum Testosterone (T) Concentrations (Cavg) Between 300 and 1000 ng/dL

Male Hypogonadism

Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)

NCT06343870Phase 3RECRUITING
Sponsor

University of Sao Paulo General Hospital

Enrollment

140

Started

2025

Primary outcome

Evaluate hormonal, metabolic thromboembolic and clinical effects on climacteric symptoms

MenopauseTestosterone DeficiencyEstrogen Deficiency

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

NCT01743235Phase 2COMPLETED
Sponsor

Emotional Brain NY Inc.

Enrollment

207

Started

2012

Primary outcome

Satisfactory Sexual Episodes

Hypoactive Sexual Desire Disorder

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164Phase 2RECRUITING
Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Enrollment

150

Started

2020

Primary outcome

Clinical or Radiographic Progression free survival

Castration Resistant Metastatic Prostate Cancer

Sexual Effects of Transdermal or Vaginal Testosterone

NCT06794346Phase 2UNKNOWN
Sponsor

University of Sao Paulo General Hospital

Enrollment

132

Started

2020

Primary outcome

Changes in sexual disorders measured by FSFI (Female Sexual Function index) after 12 and 24 weeks of treatment

Female Sexual DysfunctionPostmenopausal SymptomsTestosterone DeficiencyTestosterone Adverse Reaction

Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception

NCT00351819Phase 2COMPLETED
Sponsor

Boston University

Enrollment

84

Started

2006

Primary outcome

Brief Pain Inventory (BPI) at Week 14

PainHypogonadism

A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels

NCT01419236Phase 2COMPLETED
Sponsor

Eli Lilly and Company

Enrollment

76

Started

2011

Primary outcome

Change From Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks

Ejaculatory DysfunctionHypogonadism

Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women

NCT01724658Phase 2COMPLETED
Sponsor

Chulalongkorn University

Enrollment

70

Started

2012

Primary outcome

female sexual function index score

Female Sexual Dysfunction

Safety of Testosterone Undecanoate i.m. in Hypogonadal Men

NCT00452322Phase 2COMPLETED
Sponsor

University Hospital Muenster

Enrollment

60

Started

1997

Primary outcome

Prostate (size, PSA-level)

Hypogonadism

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

NCT06084338Phase 2RECRUITING
Sponsor

VA Office of Research and Development

Enrollment

60

Started

2023

Primary outcome

6-month radiographic progression-free survival (rPFS)

Prostate Cancer

Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients

NCT03678233Phase 2UNKNOWN
Sponsor

University Hospital, Clermont-Ferrand

Enrollment

30

Started

2019

Primary outcome

Pourcentage of patients with normal median value of serum total testosterone

Hypermetabolism in ICULoss of Muscle MassFunctional Disability After ICUICU Acquired HypogonadismTreatment With Testosterone Gel in ICU

Bipolar Androgen Therapy + Carboplatin in mCRPC

NCT03522064Phase 2RECRUITING
Sponsor

St Vincent's Hospital, Sydney

Enrollment

30

Started

2018

Primary outcome

PSA Response Rate

Castration-resistant Prostate CancerHomologous Recombination Deficiency

Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)

NCT00239590Phase 2COMPLETED
Sponsor

Imperial College London

Enrollment

28

Started

2001

Primary outcome

Myocardial Perfusion

Coronary Heart Disease

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

NCT04460872Phase 2RECRUITING
Sponsor

North Florida Foundation for Research and Education

Enrollment

21

Started

2021

Primary outcome

change in thigh muscle cross-sectional area

Spinal Cord InjurySpinal Cord InjuriesTrauma, Nervous SystemWounds and InjuryCentral Nervous System DiseasesSpinal Cord DiseasesGonadal DisordersEndocrine System DiseasesHypogonadismGenital Diseases, MaleSpinal Cord TraumaInjuries, Spinal CordWalking, DifficultyGait Disorders, NeurologicLocomotion Disorder, NeurologicWounds and InjuriesNervous System DiseasesTestosterone DeficiencyAndrogen DeficiencyHormone Deficiency

Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation

NCT00924612Phase 2COMPLETED
Sponsor

Clarus Therapeutics, Inc.

Enrollment

16

Started

2009

Primary outcome

Mean T Cavg25 Following Meals Containing Various Amounts of Dietary Fat Compared to Normal Fat Diet

Male Hypogonadism

Effect of Testosterone Treatment on Embryo Quality

NCT01662466Phase 1/2UNKNOWN
Sponsor

Center for Human Reproduction

Enrollment

180

Started

2012

Primary outcome

Clinical and Ongoing Pregnancy

Primary Ovarian InsufficiencyFemale Infertility Due to Diminished Ovarian Reserve

Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease

NCT01578473Phase 1COMPLETED
Sponsor

Men's Health Boston

Enrollment

75

Started

2013

Primary outcome

penile curvature

Peyronie's Disease

Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men

NCT00431197Phase 1COMPLETED
Sponsor

Mayo Clinic

Enrollment

40

Started

2004

Primary outcome

LH and Testosterone levels will be evaluated after 4 study visits

Hypogonadism

A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants

NCT01725451Phase 1COMPLETED
Sponsor

Eli Lilly and Company

Enrollment

30

Started

2012

Primary outcome

Pharmacokinetics: Area Under the Concentration Curve (AUC) of Testosterone

Healthy Participants

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329Phase 1TERMINATED
Sponsor

VIVUS LLC

Enrollment

16

Started

2010

Primary outcome

To measure the amount of testosterone in the blood after dosing

Hypoactive Sexual Desire Disorder

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

NCT06305598Phase 1RECRUITING
Sponsor

Roswell Park Cancer Institute

Enrollment

14

Started

2024

Primary outcome

Androgen receptor (AR) activity

Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8

Testosterone MD-Lotion Residual Washing Study

NCT00996151Phase 1COMPLETED
Sponsor

Acrux DDS Pty Ltd

Enrollment

10

Started

2009

Primary outcome

The amount of Testerone MD-Lotion 2% remaining on the axilla after a single dose application in healthy males who undergo a post dose washing procedure.

Hypergonadism

Steroid Profile: Differentiating Testosterone Administration From (Simultaneous) Ethanol Consumption

NCT04166786Phase 1COMPLETED
Sponsor

Parc de Salut Mar

Enrollment

4

Started

2019

Primary outcome

Change in steroid profile in urine

Healthy Volunteers

Testosterone Therapy in Castration Resistant Prostate Cancer

NCT03734653Early Phase 1COMPLETED
Sponsor

University of Colorado, Denver

Enrollment

30

Started

2019

Primary outcome

Feasibility of the Administration of Transdermal Testosterone Alternating with Enzalutamide

Prostate CancerCastration-Resistant Prostate Cancer

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

NCT01697345Early Phase 1COMPLETED
Sponsor

Creighton University

Enrollment

12

Started

2013

Primary outcome

Total Female Sexual Function Index (FSFI) Score

Breast CancerVaginal DrynessDyspareuniaSexual Health Quality of Life

Track your hormone research in PepStack

Log cycles, set reminders and visualize serum levels.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer